← Back to headlines
Biogen and UCB's lupus drug dapirolizumab pegol meets Phase 3 primary endpoint
The experimental lupus drug dapirolizumab pegol, developed by Biogen and UCB, has successfully met its primary goal in a Phase 3 clinical trial, marking a significant step forward in treatment options for the autoimmune disease.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Extreme Training: What Heat Training Does to the Body
just now
Police to enforce monthly environmental sanitation in Borno to fight cholera
2m ago
Oral Inflammation Linked to Reduced Fertility in New Israeli Study
8m ago
Air pollution and extreme heat linked to more migraine attacks, Israeli study finds
9m ago